Hidradenitis Suppurativa and its treatment with Humira

HUMIRA and Hidradenitis Suppurativa

Humira is used for the treatment of adults and adolescents from 12 years of age with active moderate to severe Hidradenitis Suppurativa (acne inversa) when response to other treatments is inadequate.

Create Possibilities*

Create Possibilities*

HUMIRA and Hidradenitis Suppurativa

Humira is used for the treatment of adult and adolescents from 12 years of age with active moderate to severe Hidradenitis Suppurativa (acne inversa), a chronic and often painful inflammatory skin disease.

What is Hidradenitis Suppurativa?

Hidradenitis Suppurativa (HS), is a chronic skin condition characterised by inflamed areas typically located around the armpits and groin. These inflamed areas often include painful lesions, nodules and boils.

Find out more about Hidradenitis Suppurativa

Find out more

HUMIRA Safety Information

Safety information on this website includes some of the more important information to know about HUMIRA.

How does HUMIRA work?

HUMIRA is a fully human monoclonal antibody. HUMIRA recognises and binds to a specific protein (tumour necrosis factor or TNF-alpha), which is present at increased levels in inflammatory diseases such as Hidradenitis Suppurativa.

Taking HUMIRA

What you need to know about taking HUMIRA, including helping you get the best out of your HUMIRA treatment.

*AbbVie medications and programmes are designed to support patients on their health journey.
References:

HUMIRA Approved Data Sheet
HUMIRA Approved Consumer Medical Information.
Mayo Health Clinic. Hidradenitis Suppurativa. Available at: http://www.mayoclinic.org/diseases-conditions/hidradenitis-suppurativa/home/ovc-20200012. Accessed March 28, 2019.
Jemec G. Hidradenitis Suppurativa. N Engl J Med. 2012; 366:158-64.

This site is intended for a New Zealand audience.

Important information about HUMIRA. HUMIRA is a prescription medicine containing adalimumab. HUMIRA is available as a single use pre-filled syringe or single-use pre-filled pen and may contain 20mg, 40mg or 80mg adalimumab. It is used in the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, psoriasis, ulcerative colitis, Crohn’s disease, non-infectious uveitis, and hidradenitis suppurativa. HUMIRA is only used in patients of a specific age group, in diseases of certain severity (e.g. moderate to severe), and/or after some other treatments have been tried (e.g. conventional therapy).

HUMIRA has risks and benefits. Refer to the Safety Information contained on this website for further details. If you have any questions about using HUMIRA, ask your healthcare professional and refer to the Consumer Medicine Information (CMI) available here: HUMIRA PEN CMI or HUMIRA Pre-filled Syringe CMI or by calling freephone 0800 900 030. Ask your doctor if HUMIRA is right for you. Use strictly as directed. If symptoms continue, or you have side effects, see your doctor, pharmacist or healthcare professional.

HUMIRA is a funded prescription medicine under special authorial criteria – for certain indications and patients only. Your doctor can inform you if you are eligible to receive funding. Normal pharmacy and doctor's charge will apply.

AbbVie is the company that brings you HUMIRA (adalimumab). For more information about AbbVie, visit www.AbbVie.co.nz | HUMIRA Data Sheet

AbbVie Limited, 6th floor, 156-158 Victoria street, Wellington, 6011, New Zealand 0800 900 030. HUMIRA and Destination You are registered trademarks of AbbVie Biotechnology Ltd.